title: Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes.
abstract: Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
authors.forename: Subhamoy
authors.initials: S
authors.lastname: Das
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Monteforte
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
authors.forename: Gunjan
authors.initials: G
authors.lastname: Singh
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
authors.forename: Marjan
authors.initials: M
authors.lastname: Majid
authors.affiliation: Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Sherman
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Dunn
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.|Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, USA.|Institute for Computational Engineering and Sciences (ICES), University of Texas at Austin, Austin, TX, USA.|Institute for Biomaterials, Drug Delivery and Regenerative Medicine, University of Texas at Austin, Austin, TX, USA.
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Baker
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006614:Hindlimb / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D007511:Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008081:Liposomes; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008820:Mice, Obese; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D053671:Syndecan-4 / Q000494:pharmacology*
chemical_list: D008081:Liposomes; C508306:Sdc4 protein, mouse; D053671:Syndecan-4
keywords: fibroblast growth factor-2 (FGF-2); ischemia; peripheral vascular diseases; syndecan-4; therapeutic angiogenesis